International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community.
April 13, 2024
April 13, 2024
STUDIO CITY, California, April 13 -- The International Myeloma Foundation issued the following news on April 12, 2024:
The International Myeloma Foundation (IMF) is exhilarated to share that through the leadership of the organization's Chief Scientific Officer Dr. Brian G.M. Durie and the presentations from members of the collaborative research group, the i2TEAMM, the Oncologic Drug Advisory Committee (ODAC) unanimously voted in favor (12-0) of using minimal residual disease (MRD) a . . .
The International Myeloma Foundation (IMF) is exhilarated to share that through the leadership of the organization's Chief Scientific Officer Dr. Brian G.M. Durie and the presentations from members of the collaborative research group, the i2TEAMM, the Oncologic Drug Advisory Committee (ODAC) unanimously voted in favor (12-0) of using minimal residual disease (MRD) a . . .